. 2023; 32(2): 131-137

Comparison of regadenoson and dipyridamole safety profile during stress myocardial perfusion imaging.

Jan Roczniak1, Justyna Bczalska1, Gabriela Kanclerz1, Weronika Zieliska1, Joanna Oga1, Blazej Cymerman1, Agnieszka Stpien2, Magdalena Kostkiewicz3, Katarzyna Holcman3
1Students’ Scientific Group Medical Imaging in Cardiology, Jagiellonian University Medical College, Cracow, Poland
2Jagiellonian University Medical College, Department of Cardiac and Vascular Diseases, John Paul II Hospital, Cracow, Poland
3John Paul II Hospital, Department of Nuclear Medicine, Cracow, Poland

INTRODUCTION: The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during the single photon emission computed tomography myocardial perfusion imaging. The aim of our study was to compare the frequency of the side effects of regadenoson and dipyridamole during single photon emission computed tomography myocardial perfusion imaging.
METHODS: This retrospective study included data of consecutive 283 patients who underwent pharmacological stress tests in years 2015-2020. The study group consisted of 240 patients who have received dipyridamole and 43 patients who have received regadenoson. The collected data included the patients’ characteristics, the occurrence of side effects (divided into mild: headache, vertigo, nausea, vomiting, dyspnea, chest discomfort, hot flushes, general weakness and severe: bradycardia, hypotension, loss of consciousness) and blood pressure values/measurements.
RESULTS: Overall, complications occurred relatively often (regadenoson: 23.2%, dipirydamol: 26.7%, p=0.639). Procedure discontinuation was necessary in 0.7% of examinations, whereas pharmacological support was necessary in 4.7%. There was no difference in prevalence of mild (regadenoson: 16.2%, dipirydamol: 18.3%, p=0.747) and severe complications (regadenoson: 11.6%, dipirydamol: 15.0%, p=0.563). However, regadenoson has been found to cause a significantly smaller average decrease of systolic blood pressure (regadenoson: -2.6±10.0mmHg, dipirydamol: -8.7±9.6mmHg, p=0.002), diastolic blood pressure (regadenoson: -0.9±5.4mmHg, dipirydamol: -3.6±6.2mmHg, p=0.032), as well as mean arterial pressure (regadenoson: -1.5±5.6 mmHg, dipirydamol: -5.4±6.5mmHg, p=0.001).
DISCUSSION AND CONCLUSION: Regadenoson and dipyridamole presented a similar safety profile during single photon emission computed tomography myocardial perfusion imaging. However, regadenoson has been found to cause significantly smaller decreases in systolic blood pressure, diastolic blood pressure, mean arterial pressure.

Keywords: regadenoson, dipyridamole, myocardial perfusion imaging, vasodilators, stress test, single photon emission computed tomography


Jan Roczniak, Justyna Bczalska, Gabriela Kanclerz, Weronika Zieliska, Joanna Oga, Blazej Cymerman, Agnieszka Stpien, Magdalena Kostkiewicz, Katarzyna Holcman. Comparison of regadenoson and dipyridamole safety profile during stress myocardial perfusion imaging.. . 2023; 32(2): 131-137

Corresponding Author: Jan Roczniak, Poland


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
Google Scholar